# Investigational Therapeutics for the Treatment of People With Ebola Virus Disease

> **NCT03719586** · PHASE2,PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 681 (actual)

## Conditions studied

- Ebola Virus

## Interventions

- **DRUG:** ZMapp
- **DRUG:** Remdesivir
- **DRUG:** MAb114
- **DRUG:** REGN-EB3

## Key facts

- **NCT ID:** NCT03719586
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-21
- **Primary completion:** 2019-09-09
- **Final completion:** 2020-08-18
- **Target enrollment:** 681 (ACTUAL)
- **Last updated:** 2021-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03719586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03719586, "Investigational Therapeutics for the Treatment of People With Ebola Virus Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03719586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*